Radiosensitivity Predictive Test
Prediction of radiotherapy toxicity/efficacy across cancer types
Pre-clinical/Clinical ValidationActive
Key Facts
Indication
Prediction of radiotherapy toxicity/efficacy across cancer types
Phase
Pre-clinical/Clinical Validation
Status
Active
Company
About Neolys Diagnostics
Neolys Diagnostics is a private, pre-revenue diagnostics company focused on personalized radiotherapy in oncology. Its core technology leverages over a decade of academic research, primarily from INSERM in Lyon, to create predictive tests that measure a patient's individual radiosensitivity via ATM protein analysis in blood or tissue samples. This aims to help clinicians optimize radiation dosing, improving efficacy and reducing toxicity. The company is in the development and clinical validation stage, building partnerships across Europe.
View full company profile